Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson's Disease: Real-World Evidence From G7 Countries.
Antonini A, Pahwa R, Odin P, Henriksen T, Soileau MJ, Rodriguez-Cruz R, Isaacson SH, Merola A, Lindvall S, Domingos J, Alobaidi A, Jalundhwala YJ, Kandukuri PL, Parra JC, Kukreja PK, Onuk K, Bergmann L, Pike J, Ray Chaudhuri K. Antonini A, et al. Among authors: kandukuri pl. Neurol Ther. 2022 Mar;11(1):303-318. doi: 10.1007/s40120-021-00313-9. Epub 2022 Jan 11. Neurol Ther. 2022. PMID: 35015215 Free PMC article.
Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries.
Malaty IA, Martinez-Martin P, Chaudhuri KR, Odin P, Skorvanek M, Jimenez-Shahed J, Soileau MJ, Lindvall S, Domingos J, Jones S, Alobaidi A, Jalundhwala YJ, Kandukuri PL, Onuk K, Bergmann L, Femia S, Lee MY, Wright J, Antonini A. Malaty IA, et al. Among authors: kandukuri pl. BMC Neurol. 2022 Jan 24;22(1):35. doi: 10.1186/s12883-022-02560-1. BMC Neurol. 2022. PMID: 35073872 Free PMC article.
Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson's Disease: Clinical Trial Post Hoc Analyses.
Pahwa R, Aldred J, Gupta N, Terasawa E, Garcia-Horton V, Steffen DR, Kandukuri PL, Chaudhari VS, Jalundhwala YJ, Bao Y, Kukreja P, Isaacson SH. Pahwa R, et al. Among authors: kandukuri pl. Neurol Ther. 2022 Jun;11(2):711-723. doi: 10.1007/s40120-022-00332-0. Epub 2022 Feb 22. Neurol Ther. 2022. PMID: 35192177 Free PMC article.
Comparative Effectiveness of Carbidopa-Levodopa Enteral Suspension and Deep Brain Stimulation on Parkinson's Disease-Related Pill Burden Reduction in Advanced Parkinson's Disease: A Retrospective Real-World Cohort Study.
Soileau MJ, Pagan F, Fasano A, Rodriguez-Cruz R, Wang L, Kandukuri PL, Yan CH, Alobaidi A, Bao Y, Kukreja P, Oh M, Siddiqui MS. Soileau MJ, et al. Among authors: kandukuri pl. Neurol Ther. 2022 Jun;11(2):851-861. doi: 10.1007/s40120-022-00351-x. Epub 2022 Apr 20. Neurol Ther. 2022. PMID: 35441973 Free PMC article.
The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England.
Chaudhuri KR, Pickard AS, Alobaidi A, Jalundhwala YJ, Kandukuri PL, Bao Y, Sus J, Jones G, Ridley C, Oddsdottir J, Najle-Rahim S, Madin-Warburton M, Xu W, Schrag A. Chaudhuri KR, et al. Among authors: kandukuri pl. Pharmacoeconomics. 2022 May;40(5):559-574. doi: 10.1007/s40273-022-01132-y. Epub 2022 Mar 21. Pharmacoeconomics. 2022. PMID: 35307793 Free PMC article.
Use of a medication-based algorithm to identify advanced Parkinson's disease in administrative claims data: Associations with claims-based indicators of disease severity.
Dahodwala N, Pettit AR, Jahnke J, Li P, Ladage VP, Kandukuri PL, Zamudio J, Jalundhwala YJ, Doshi JA. Dahodwala N, et al. Among authors: kandukuri pl. Clin Park Relat Disord. 2020 Feb 26;3:100046. doi: 10.1016/j.prdoa.2020.100046. eCollection 2020. Clin Park Relat Disord. 2020. PMID: 34316631 Free PMC article.
Seek COVER: using a disease proxy to rapidly develop and validate a personalized risk calculator for COVID-19 outcomes in an international network.
Williams RD, Markus AF, Yang C, Duarte-Salles T, DuVall SL, Falconer T, Jonnagaddala J, Kim C, Rho Y, Williams AE, Machado AA, An MH, Aragón M, Areia C, Burn E, Choi YH, Drakos I, Abrahão MTF, Fernández-Bertolín S, Hripcsak G, Kaas-Hansen BS, Kandukuri PL, Kors JA, Kostka K, Liaw ST, Lynch KE, Machnicki G, Matheny ME, Morales D, Nyberg F, Park RW, Prats-Uribe A, Pratt N, Rao G, Reich CG, Rivera M, Seinen T, Shoaibi A, Spotnitz ME, Steyerberg EW, Suchard MA, You SC, Zhang L, Zhou L, Ryan PB, Prieto-Alhambra D, Reps JM, Rijnbeek PR. Williams RD, et al. Among authors: kandukuri pl. BMC Med Res Methodol. 2022 Jan 30;22(1):35. doi: 10.1186/s12874-022-01505-z. BMC Med Res Methodol. 2022. PMID: 35094685 Free PMC article.
Economic Burden of Parkinson's Disease: A Multinational, Real-World, Cost-of-Illness Study.
Chaudhuri KR, Azulay JP, Odin P, Lindvall S, Domingos J, Alobaidi A, Kandukuri PL, Chaudhari VS, Parra JC, Yamazaki T, Oddsdottir J, Wright J, Martinez-Martin P. Chaudhuri KR, et al. Among authors: kandukuri pl. Drugs Real World Outcomes. 2024 Mar;11(1):1-11. doi: 10.1007/s40801-023-00410-1. Epub 2024 Jan 9. Drugs Real World Outcomes. 2024. PMID: 38193999 Free PMC article.
15 results